V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10275478 | 10058051 | 1.77 | 56.55 | Adjuvant (A) | 2018-06-28 | 2019-04-06 | Eribulin | 02 | null | FLAIR TRIAL | 101464786 |
| 10277286 | 10058054 | 1.61 | 82.3 | null | 2019-08-18 | 2019-09-02 | null | 02 | null | FLUOROURACIL + MITOMYCIN | 101098670 |
| 10277622 | 10058056 | 1.84 | 65.5 | Palliative (P) | 2021-04-17 | 2021-04-25 | Pertuzumab (Maintenance) | 02 | N | NINTEDANIB | 100962482 |
| 10278761 | 10058059 | 1.71 | 101.5 | null | 2014-02-16 | 2016-03-04 | PCV | N | null | DOXORUBICIN EMBOLISATION | 100066444 |
| 10280266 | 10058062 | 1.76 | 88 | null | 2018-10-14 | 2019-01-21 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | null | DOXORUBICIN EMBOLISATION | 100528963 |
| 10281533 | 10058065 | 1.94 | 63.8 | null | 2019-11-30 | 2019-11-30 | EC | N | null | DURVALUMAB | 100107109 |
| 10282528 | 10058066 | 1.7 | 67.5 | Curative (C) | 2017-03-14 | 2017-07-25 | null | 02 | N | ANAGRELIDE | 101086635 |
| 10283968 | 10058068 | 1.76 | 89 | Palliative (P) | 2019-03-08 | 2019-04-23 | Pemetrexed | 02 | N | NOT MATCHED | 100620638 |
| 10284652 | 10058070 | 1.81 | 89 | null | 2018-11-10 | 2018-11-10 | EVEROLIMUS + LENVATINIB | null | null | CHLORAMBUCIL + RITUXIMAB | 100409135 |
| 10284728 | 10058071 | 1.69 | 68 | Palliative (P) | 2020-05-13 | 2020-07-15 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | N | CARBOPLATIN + CETUXIMAB + FU | 101658494 |
| 10284794 | 10058072 | 1.68 | 61.9 | Palliative (P) | 2019-06-12 | 2019-06-12 | STAMPEDE TRIAL | 02 | N | CARBOPLATIN + FLUOROURACIL | 101036641 |
| 10285735 | 10058073 | 1.68 | 96.1 | Palliative (P) | 2019-11-26 | 2019-12-12 | Cladribine + Rituximab | 02 | N | FLUOROURACIL + MITOMYCIN | 100919886 |
| 10288877 | 10058077 | null | null | Palliative (P) | 2019-05-22 | 2019-06-14 | EVEROLIMUS + LENVATINIB | 02 | null | IXAZOMIB | 101845802 |
| 10289862 | 10058080 | 1.62 | 60.7 | Neo-adjuvant (N) | 2020-11-20 | 2020-11-23 | Zanubrutinib | 02 | N | AVELUMAB + AXITINIB | 101392804 |
| 10289946 | 10058081 | 1.65 | 52 | Palliative (P) | 2020-05-30 | 2020-06-18 | null | 02 | N | DASATINIB | 100434061 |
| 10292516 | 10058083 | 1.7 | 67.5 | null | 2016-06-27 | 2016-06-30 | TRASTUZUMAB EMTANSINE | 02 | null | BEVACIZUMAB | 101556712 |
| 10294472 | 10058086 | 1.82 | 70.4 | null | 2019-07-07 | 2019-07-07 | null | 02 | null | IRINOTECAN | 101787456 |
| 10296424 | 10058088 | 1.69 | 0 | Palliative (P) | null | 2021-10-02 | Cyclophosphamide High Dose | 02 | N | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100068559 |
| 10296487 | 10058089 | 0 | 0 | null | 2018-04-01 | 2018-04-03 | Bevacizumab 7.5mg/kg | 02 | null | DURVALUMAB | 100596748 |
| 10296794 | 10058090 | 1.7 | 108.5 | 03 | 2019-12-12 | 2020-01-03 | Bevacizumab+Carbo+Pacliaxel | 02 | N | FIGARO TRIAL | 100794867 |
| 10297559 | 10058092 | 1.71 | 88.8 | Disease modification (D) | 2019-02-23 | 2020-05-16 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | Y | MATRIX LUNG TRIAL | 100394923 |
| 10298241 | 10058095 | 1.81 | 70 | null | 2018-09-17 | 2018-09-17 | null | 02 | null | CAPECITABINE + CISPLATIN | 101248899 |
| 10298584 | 10058097 | 1.54 | 83 | null | 2022-03-06 | 2022-03-14 | R Chlorambucil | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL | 101166478 |
| 10299466 | 10058100 | 1.63 | 65.7 | null | 2020-05-24 | 2020-12-21 | EOX | 02 | null | CARBOPLATIN + FLUOROURACIL | 101121422 |
| 10299756 | 10058101 | 1.54 | 59.6 | null | 2018-07-04 | 2018-11-15 | CISPLATIN + GEMCITABINE + RITUXIMAB | 02 | null | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101632350 |
| 10300110 | 10058104 | 1.56 | 79.4 | Palliative (P) | 2019-06-09 | 2019-06-19 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | 02 | N | CYTARABINE + OXALIPLATIN | 101070572 |
| 10302282 | 10058107 | 1.53 | 52.25 | null | 2018-02-21 | 2018-03-21 | TRASTUZUMAB EMTANSINE | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101319467 |
| 10302602 | 10058108 | 1.55 | 82.8 | 03 | 2018-11-28 | 2019-02-12 | Capecitabine + Mitomycin | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100733846 |
| 10303134 | 10058110 | 1.61 | 70.7 | null | 2008-02-01 | 2018-03-12 | CHLORAMBUCIL + DEXAMETHASONE + DEXAMETHASONE + ETOPOSIDE | 02 | null | TRIAL | 101768203 |
| 10303318 | 10058111 | 1.75 | 71 | Palliative (P) | 2021-12-11 | 2021-12-11 | GEMCITABINE + PACLITAXEL ALBUMIN (ABRAXANE) | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL | 100167892 |
| 10306520 | 10058116 | 1.52 | 68 | null | 2020-05-17 | 2020-05-19 | null | 02 | null | CISPLATIN + PEMETREXED | 101684894 |
| 10306923 | 10058117 | 1.56 | 87 | Curative (C) | null | 2016-06-20 | null | 01 | N | LIPOSOMAL DOXORUBICIN | 101407948 |
| 10308206 | 10058119 | 1.69 | 55.3 | null | null | 2018-12-01 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | null | FULVESTRANT + RIBOCICLIB | 101841523 |
| 10334145 | 10058125 | 1.55 | 98 | null | 2019-09-13 | 2019-09-19 | Carboplatin + Cetux + FU (>Cycle 2) | null | null | OBINUTUZUMAB + VENETOCLAX | 100341415 |
| 10335464 | 10058126 | 0 | 47.2 | Palliative (P) | 2019-12-04 | 2019-12-08 | Cytarabine low (10to20mg/m2) IV/SC | 02 | N | OXALIPLATIN + RALTITREXED | 100837378 |
| 10337274 | 10058129 | 1.72 | 79.4 | Curative (C) | 2019-09-25 | 2019-10-22 | R GCVP | 01 | N | BORTEZOMIB + PANOBINOSTAT + THALIDOMIDE | 100832100 |
| 10337455 | 10058130 | 1.67 | 76.4 | Palliative (P) | 2021-10-09 | 2021-10-14 | Topotecan (intravenous) | 2 | N | PEMBROLIZUMAB + PEMETREXED | 100107589 |
| 10338096 | 10058131 | 1.64 | 71.3 | Adjuvant (A) | 2019-05-18 | 2019-05-20 | Cyclophos + Dex + Lenalidomide | 02 | N | ABEMACICLIB + FULVESTRANT | 100994453 |
| 10339239 | 10058133 | 1.57 | 0 | Neo-adjuvant (N) | 2020-01-15 | 2020-02-04 | null | null | N | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB | 101545721 |
| 10340007 | 10058137 | 1.75 | 63.3 | null | 2020-02-24 | 2020-03-02 | Bevacizumab+Carbo+Pacliaxel | 02 | null | REGORAFENIB | 101460337 |
| 10341355 | 10058138 | 1.83 | 58 | Adjuvant (A) | null | 2017-05-08 | Obinutuzumab | 02 | N | TRIAL | 100889186 |
| 10341785 | 10058139 | 1.93 | 57.5 | Curative (C) | 2019-12-19 | 2019-12-20 | IDELALISIB | null | N | CARFILZOMIB | 100988540 |
| 10342392 | 10058142 | null | null | 03 | 2016-08-15 | 2016-08-17 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | N | TRIAL | 100550491 |
| 10343466 | 10058146 | 1.7 | 61.9 | Curative (C) | 2020-09-02 | 2020-09-17 | Abemaciclib | 02 | N | OSIMERTINIB | 100303144 |
| 10346358 | 10058149 | 0 | 75 | Palliative (P) | 2019-11-25 | 2019-12-02 | STAMPEDE TRIAL | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101808960 |
| 10346604 | 10058150 | 1.68 | 46.1 | null | 2020-01-19 | 2020-02-01 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | null | BENDAMUSTINE | 100484157 |
| 10348373 | 10058158 | 1.67 | 74.6 | 03 | 2015-03-14 | 2020-10-14 | CAPECITABINE + TEMOZOLOMIDE | 02 | Y | CYTARABINE + ETOPOSIDE + LOMUSTINE + MELPHALAN | 101246639 |
| 10348598 | 10058159 | 1.65 | 59 | 03 | 2022-03-13 | 2022-03-13 | LENVATINIB | N | N | FCR | 101364972 |
| 10348886 | 10058160 | 1.67 | 62 | Palliative (P) | 2021-10-12 | 2021-11-03 | BENDAMUSTINE + CYTARABINE + RITUXIMAB | N | N | TEMOZOLOMIDE + RT | 101262326 |
| 10349649 | 10058164 | 1.55 | 92 | Palliative (P) | 2021-04-19 | 2021-04-19 | STAMPEDE TRIAL | 02 | N | TISAGENLECLEUCEL (KYMRIAH) + FLUDARABINE + CYCLOPHOSPHAMIDE | 101789148 |